Fulcrum Therapeutics (FULC) Operating Expenses (2020 - 2025)
Historic Operating Expenses for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to $21.9 million.
- Fulcrum Therapeutics' Operating Expenses fell 1300.64% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.1 million, marking a year-over-year decrease of 4511.68%. This contributed to the annual value of $101.9 million for FY2024, which is 1019.84% down from last year.
- Latest data reveals that Fulcrum Therapeutics reported Operating Expenses of $21.9 million as of Q3 2025, which was down 1300.64% from $19.8 million recorded in Q2 2025.
- Fulcrum Therapeutics' Operating Expenses' 5-year high stood at $36.1 million during Q2 2022, with a 5-year trough of $19.4 million in Q4 2024.
- In the last 5 years, Fulcrum Therapeutics' Operating Expenses had a median value of $27.8 million in 2023 and averaged $26.5 million.
- Per our database at Business Quant, Fulcrum Therapeutics' Operating Expenses surged by 5009.35% in 2022 and then crashed by 3268.54% in 2024.
- Over the past 5 years, Fulcrum Therapeutics' Operating Expenses (Quarter) stood at $28.6 million in 2021, then rose by 0.14% to $28.7 million in 2022, then increased by 0.72% to $28.9 million in 2023, then plummeted by 32.69% to $19.4 million in 2024, then grew by 12.5% to $21.9 million in 2025.
- Its Operating Expenses stands at $21.9 million for Q3 2025, versus $19.8 million for Q2 2025 and $19.4 million for Q4 2024.